Aussie MP Calls For Review Of Coverage of Strattera ADHD Drug
This article was originally published in PharmAsia News
Executive Summary
An Australia Parliament member is calling for the national health system to reconsider covering the cost of Eli Lilly's Stratterra (atomoxetine) for treating attention deficit hyperactivity disorder in children.